{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-22-000133","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.873173+00:00","generated_at":"2026-06-22T06:18:01.703173+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ligand Q3 revenue $66.1M (+2% YoY); raises 2022 guidance; completes OmniAb spin-off","bullets":["Q3 GAAP net income $0.4M ($0.02 EPS) vs $13.7M ($0.80) YoY; adjusted EPS $1.31 vs $1.58.","Q3 royalty revenue up 27% to $19.8M on Kyprolis, Rylaze, Teriparatide; total revenue $66.1M.","2022 guidance raised: total revenue $184-189M (prior $133-146M); adjusted EPS $4.30-$4.45.","Completed tax-free spin-off of OmniAb on Nov 1; OmniAb began trading as OABI on Nov 2.","Repurchased $38.6M principal of 2023 Notes for $37.7M; cash & investments $121.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-22-000133","json":"https://secwatch.observer/filing/0000886163-22-000133.json","markdown":"https://secwatch.observer/filing/0000886163-22-000133.md","text":"https://secwatch.observer/filing/0000886163-22-000133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000133/0000886163-22-000133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000133/lgnd-20221107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T06:18:01.703173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe71541c4925d73bdf074d5ae811dfc681240588","claim":"LIGAND PHARMACEUTICALS INC updated its the three and nine months ended September 30, 2022 guidance (raised).","evidence_excerpt":"On November 7, 2022, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000133/0000886163-22-000133-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2022"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}